China PK Bridging Study Design for Foreign Medical Products

This guide outlines the design considerations for conducting pharmacokinetic (PK) bridging studies in China for foreign medical products. It emphasizes the importance of conducting a China PK study in parallel with pivotal studies, provided certain criteria are met, such as low risks of ethnicity differences and the fulfillment of unmet medical needs in China. The document details two primary approaches for study design: a separate China PK study conducted alongside a pivotal study, and embedding the China PK study within the pivotal study itself. Key considerations for bridging study design are also presented, including the necessity of successful outcomes in global pivotal studies, the applicability of dosage regimens, and the ability to extrapolate safety and efficacy profiles from global data to the Chinese population. Additionally, the guide discusses strategies to streamline the bridging study process, such as choosing between controlled and single-arm designs and analyzing trends in data. Overall, it provides a comprehensive framework for optimizing market entry for foreign medical products in China.